Xunrong Luo

Xunrong Luo

Auto-generated profile, based on publicly available information

Xunrong Luo

Department of Medicine, Division of Nephrology, Duke University, Durham, NC

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XLXunrong Luo
Xunrong Luo
KPKathryn L. Pothoven
Kathryn L. Pothoven
DMDerrick McCarthy
Derrick McCarthy
MDMathew DeGutes
Mathew DeGutes
AMAaron Martin
Aaron Martin
SMStephen D. Miller
Stephen D. Miller
A major challenge for human allogeneic islet transplantation is the development of effective methods to induce donor-specific tolerance to obviate the need for life-long immunosuppression that is toxic to the insulin-producing β cells and detrimental to the host. We developed an efficient donor-specific tolerance therapy that utilizes infusions of ethylene carbodiimide (ECDI)-treated donor splenic antigen-presenting cells that results in indefinite survival of allogeneic islet grafts in the absence of immunosuppression. Furthermore, we show that induction of tolerance is critically dependent on synergistic effects between an intact programmed death 1 receptor–programmed death ligand 1 signaling pathway and CD4+CD25+Foxp3+regulatory T cells. This highly efficient antigen-specific therapy with a complete avoidance of immunosuppression has significant therapeutic potential in human islet cell transplantation.

9 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
JMJames F. Markmann
James F. Markmann
MRMichael R. Rickels
Michael R. Rickels
TEThomas L. Eggerman
Thomas L. Eggerman
NBNancy D. Bridges
Nancy D. Bridges
DLDavid E. Lafontant
David E. Lafontant
NTNicole A. Turgeon
Nicole A. Turgeon
Allogeneic islet transplant offers a minimally invasive option for β cell replacement in the treatment of type 1 diabetes (T1D). The CIT consortium trial of purified human pancreatic islets (PHPI) in patients with T1D after kidney transplant (CIT06), a National Institutes of Health-sponsored phase 3, prospective, open-label, single-arm pivotal trial of PHPI, was conducted in 24 patients with impaired awareness of hypoglycemia while receiving intensive insulin therapy. PHPI were manufactured using standardized processes. PHPI transplantation was effective with 62.5% of patients achieving the primary endpoint of freedom from severe hypoglycemic events and HbA1c ≤ 6.5% or reduced by ≥ 1 percentage point at 1 year posttransplant. Median HbA1c declined from 8.1% before to 6.0% at 1 year and 6.3% at 2 and 3 years following transplant (P < .001 for all vs baseline), with related improvements in hypoglycemia awareness and glucose variability. The improved metabolic control was associated with better health-related and diabetes-related quality of life. The procedure was safe and kidney allograft function remained stable after 3 years. These results add to evidence establishing allogeneic islet transplant as a safe and effective treatment for patients with T1D and unstable glucose control despite intensive insulin treatment, supporting the indication for PHPI in the post-renal transplant setting.

15 July 2012 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TKTaba Kheradmand
Taba Kheradmand
SWShusen Wang
Shusen Wang
JBJane Bryant
Jane Bryant
JTJames J. Tasch
James J. Tasch
NLNadine Lerret
Nadine Lerret
XLXunrong Luo
Xunrong Luo
Strategic exposure to donor Ags prior to transplantation can be an effective way for inducting donor-specific tolerance in allogeneic recipients. We have recently shown that pretransplant infusion of donor splenocytes treated with the chemical cross-linker ethylenecarbodiimide (ECDI-SPs) induces indefinite islet allograft survival in a full MHC-mismatched model without the need for any immunosuppression. Mechanisms of allograft protection by this strategy remain elusive. In this study, we show that the infused donor ECDI-SPs differentially target T cells with indirect versus direct allospecificities. To target indirect allospecific T cells, ECDI-SPs induce upregulation of negative, but not positive, costimulatory molecules on recipient splenic CD11c+ dendritic cells phagocytosing the injected ECDI-SPs. Indirect allospecific T cells activated by such CD11c+ dendritic cells undergo robust initial proliferation followed by rapid clonal depletion. The remaining T cells are sequestered in the spleen without homing to the graft site or the graft draining lymph node. In contrast, direct allospecific T cells interacting with intact donor ECDI-SPs not yet phagocytosed undergo limited proliferation and are subsequently anergized. Furthermore, CD4+CD25+Foxp3+ T cells are induced in lymphoid organs and at the graft site by ECDI-SPs. We conclude that donor ECDI-SP infusions target host allogeneic responses via a multitude of mechanisms, including clonal depletion, anergy, and immunoregulation, which act in a synergistic fashion to induce robust transplant tolerance. This simple form of negative vaccination has significant potential for clinical translation in human transplantation.

11 July 2016 in Annual Review of Biomedical Engineering
Verified
Journal Article
Closed access
XLXunrong Luo
Xunrong Luo
SMStephen D. Miller
Stephen D. Miller
LSLonnie D Shea
Lonnie D Shea
The undesired destruction of healthy cells, either endogenous or transplanted, by the immune system results in the loss of tissue function or limits strategies to restore tissue function. Current therapies typically involve nonspecific immunosuppression that may prevent the appropriate response to an antigen, thereby decreasing humoral immunity and increasing the risks of patient susceptibility to opportunistic infections, viral reactivation, and neoplasia. The induction of antigen-specific immunological tolerance to block undesired immune responses to self- or allogeneic antigens, while maintaining the integrity of the remaining immune system, has the potential to transform the current treatment of autoimmune disease and serve as a key enabling technology for therapies based on cell transplantation.

1 October 2014 in Biomaterials
Verified
Journal Article
Closed access
JBJane Bryant
Jane Bryant
KHKelan A. Hlavaty
Kelan A. Hlavaty
XZXiaomin Zhang
Xiaomin Zhang
WYWoon-Teck Yap
Woon-Teck Yap
LZLei Zhang
Lei Zhang
XLXunrong Luo
Xunrong Luo

1 March 2008 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
XLXunrong Luo
Xunrong Luo
QZQiang Zhang
Qiang Zhang
VLVictoria Liu
Victoria Liu
ZXZhenbiao Xia
Zhenbiao Xia
KPKathryn L. Pothoven
Kathryn L. Pothoven
CLChung Lee
Chung Lee
The peripheral induction of T regulatory cells can be accomplished by TGF-β through an epigenetic regulation leading to the expression of Foxp3. However, the exact mechanism of such a TGF-β-mediated action remains unclear. In the current study, we found that TGF-β treatment of CD4+CD25− T cells during T cell activation led to a transient inhibition of the phosphorylation of ERK followed by the induction of Foxp3 expression in these cells. Direct treatment with a specific ERK inhibitor, UO126, during CD4+CD25− T cell activation also induced Foxp3 expression and conferred a suppressive function to the induced Foxp3+ T cells. Furthermore, treatment of T cells with either TGF-β or UO126 significantly down-regulated the expression of DNMTs, a reaction normally elicited by demethylation agents, such as 5-Aza-2′-deoxycytidine. These results indicate that the epigenetic regulation of TGF-β-induced expression of Foxp3 may be mediated through the inactivation of ERK.